Temperature-stable tuberculosis vaccine prompts immune response 12-Apr-2023 By Rachel Arthur A Phase 1 trial found that a freeze-dried, temperature-stable experimental tuberculosis vaccine was safe, well-tolerated and elicited robust antigen-specific serum antibody and Th1-type cellular immune responses.
Sanofi commits to €400m annual investment in mRNA vaccines 01-Jul-2021 By Ben Hargreaves After the success of COVID-19 mRNA vaccines, the company takes the decision as part of a ‘long-term play’ to target diseases beyond the pandemic.